Lycan TW, Hsu FC, Ahn CS, et al. - In this cross-sectional study, researchers tested neuromuscular ultrasound (NMUS) as a non-invasive, point-of-care test to measure nerve cross-sectional area (CSA) in patients with active taxane chemotherapy-induced peripheral neuropathy (CIPN) symptoms with the assumption that nerve CSA would be altered. The sample consisted of breast cancer patients with taxane CIPN measured nerve CSA by NMUS and compared with healthy historical controls. Twenty participants reported moderate symptoms of CIPN at a median of 3.8 months after the last taxane dose. Data reported that sural nerve CSA was 1.2 mm² smaller than healthy controls. Older age and time since taxane were linked to smaller sural nerve CSA. Distal IENFD decreased by 2.1 nerve/mm for each 1 mm² decreases in sural nerve CSA. Such findings encourage a sensory predominant taxane neuropathy or neuronopathy and warrant future research on CIPN's longitudinal NMUS assessment.